TC
VYGR icon

Truvestments Capital’s Voyager Therapeutics VYGR Stock Holding History

Truvestments Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-330
Closed -$1.27K – 1297
2026
Q1 		$1.27K Sell
330
-476
-59% -$1.87K ﹤0.01% 1034
2025
Q4 		$3.17K Sell
806
-1
-0.1% -$4 ﹤0.01% 852
2025
Q3 		$3.77K Sell
807
-899
-53% -$3.25K ﹤0.01% 868
2025
Q2 		$5.31K Buy
1,706
+1
+0.1% +$3 ﹤0.01% 728
2025
Q1 		$5.76K Sell
1,705
-265
-13% -$1.24K ﹤0.01% 741
2024
Q4 		$11.2K Buy
1,970
+1,076
+120% +$6.94K ﹤0.01% 582
2024
Q3 		$5.23K Buy
+894
New +$6.5K ﹤0.01% 679

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Truvestments Capital's VYGR Position: Q2 2026 in Review

Truvestments Capital sold out of Voyager Therapeutics (VYGR) in Q2 2026, closing a stake of 330 shares — an estimated $1.27K sold.

Truvestments Capital first reported a position in VYGR in Q3 2024 and held it in 7 quarters. The position peaked at $11.2K in Q4 2024. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Truvestments Capital reported no remaining Voyager Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Truvestments Capital sold 330 Voyager Therapeutics shares in Q2 2026, an estimated $1.27K.
  • Truvestments Capital first reported a position in Voyager Therapeutics in Q3 2024 and held it in 7 quarters.
  • Truvestments Capital's Voyager Therapeutics position peaked at $11.2K in Q4 2024.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.